🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Fateeha Furqan

The University of Texas MD Anderson Cancer Center

ORCID: 0000-0001-7262-4953

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel).”.

Prognostic impact of dose, duration, and timing of corticosteroid therapy in patients with large B-cell lymphoma treated with standard of care axicabtagene ciloleucel (Axi-cel).

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.8011

N/A

0.470DataRank · unranked

22 citations

Fateeha Furqan, Jason R. Westin, Luis Fayad, Sairah Ahmed, Hun Ju Lee +15 more

Autologous stem cell rescue recipient with neutrophil tissue delivery detected prior to blood engraftment: A case report

eJHaem(2020)10.1002/jha2.65

N/A

0DataRank · unranked

2 citations

Fateeha Furqan, Glynis Scott, Jane L. Liesveld, Omar S. Aljitawi, Bushra Tbakhi

Phase II Trial of Axicabagene Ciloleucel and Glofitamab As Second-Line Therapy for Patients with Relapsed or Refractory Large B-Cell Lymphoma

Blood(2024)10.1182/blood-2024-205196

N/A

0DataRank · unranked

4 citations

Dai Chihara, Luis Fayad, Sattva S. Neelapu, Sairah Ahmed, Frederick Hagemeister +11 more